Page last updated: 2024-11-05

ticlopidine and Necrosis

ticlopidine has been researched along with Necrosis in 22 studies

Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.

Necrosis: The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.

Research Excerpts

ExcerptRelevanceReference
"We compared the effects of a 600- versus a 300-mg LD of clopidogrel on inhibition of platelet aggregation, myonecrosis, and clinical outcomes in patients with NSTEACS undergoing an early invasive management strategy."9.14Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin ( Brieger, D; Chew, DP; Dick, R; Eccleston, D; Eikelboom, JW; Ferguson, L; French, J; Hockings, B; Rankin, J; Thom, J; Walters, D; Whelan, A; Yong, G, 2009)
"The purpose of this study was to evaluate the effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention (PCI) with glycoprotein (GP) IIb/IIIa blockade."9.13The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy. ( Buller, C; Densem, C; Fox, R; Fung, A; Jokhi, P; Mancini, GB; Ricci, D; Saw, J; Starovoytov, A; Walsh, S; Wong, G, 2008)
"A strategy of clopidogrel with GP IIb/IIIa blockade resulted in superior inhibition of inflammation and cardiac marker release, which was accompanied by superior platelet inhibition immediately after percutaneous coronary intervention compared with a strategy of clopidogrel alone."9.12Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study. ( Bliden, KP; Gurbel, PA; Tantry, US, 2006)
"In patients with NSTE-ACS undergoing early invasive strategy, the adjunctive administration of upstream tirofiban did not reduce the peak values and the cumulative release of myocardial necrosis markers, compared with aspirin, heparin, and clopidogrel given on admission and associated with selective use of abciximab just before PCI."9.11Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstrea ( Badia, T; Bellandi, F; Dabizzi, RP; De Servi, S; Leoncini, M; Maioli, M; Politi, A; Toso, A, 2005)
"We sought to evaluate the influence of platelet reactivity after clopidogrel, as assessed by the VerifyNow point-of-care assay (Accumetrics, San Diego, California), on myonecrosis in low-to-intermediate risk patients undergoing percutaneous coronary intervention (PCI)."7.76Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention. ( Barbato, E; D'Ambrosio, A; Di Sciascio, G; Gatto, L; Mangiacapra, F; Patti, G; Ricottini, E; Vizzi, V; Wijns, W, 2010)
" A significant dose-response was also observed for the vasodilator-stimulated phosphoprotein index, a measure of P2Y(12) receptor inhibition."6.72A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) t ( Bal-dit-Sollier, C; Beygui, F; Collet, JP; Drouet, L; Henry, P; Lellouche, N; Meuleman, C; Milleron, O; Montalescot, G; Sideris, G; Slama, M; Steg, PG, 2006)
"Aspirin response was assessed by measuring the residual ability of platelets to generate thromboxane, calculated as the difference between thromboxane B2 levels in serum and plasma, [TxB2]S-P."5.42Dual antiplatelet response during PCI: VerifyNow P2Y12 predicts myocardial necrosis and thromboxane B2 generation confirms wide variation in aspirin response. ( Good, RI; Goodall, AH; James, TE; McConnachie, A; McGarrity, A; Miller, H; Oldroyd, KG, 2015)
"In the PRATO-ACS trial, 504 consecutive statin-naïve non-ST-elevation acute coronary syndrome patients scheduled for early invasive strategy and pretreated with high-dose clopidogrel were randomly assigned to rosuvastatin (40 mg on admission followed by 20 mg/d; statin group, n = 252) or no statin treatment (control group, n = 252)."5.19Early high-dose rosuvastatin and cardioprotection in the protective effect of rosuvastatin and antiplatelet therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome (PRATO-ACS) study. ( Badia, T; Bellandi, F; Leoncini, M; Maioli, M; Toso, A; Tropeano, F; Villani, S, 2014)
"We compared the effects of a 600- versus a 300-mg LD of clopidogrel on inhibition of platelet aggregation, myonecrosis, and clinical outcomes in patients with NSTEACS undergoing an early invasive management strategy."5.14Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin ( Brieger, D; Chew, DP; Dick, R; Eccleston, D; Eikelboom, JW; Ferguson, L; French, J; Hockings, B; Rankin, J; Thom, J; Walters, D; Whelan, A; Yong, G, 2009)
"The purpose of this study was to evaluate the effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention (PCI) with glycoprotein (GP) IIb/IIIa blockade."5.13The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy. ( Buller, C; Densem, C; Fox, R; Fung, A; Jokhi, P; Mancini, GB; Ricci, D; Saw, J; Starovoytov, A; Walsh, S; Wong, G, 2008)
"1% male) patients receiving 300 mg daily enteric coated aspirin for at least 7 days with documented coronary artery disease were included in the study."5.13Effects of persistent platelet reactivity despite aspirin therapy on cardiac troponin I and creatine kinase-MB levels after elective percutaneous coronary interventions. ( Aydinalp, A; Ertan, C; Gulmez, O; Kaynar, G; Konas, D; Muderrisoglu, H; Ozin, B; Yildirir, A, 2008)
"A strategy of clopidogrel with GP IIb/IIIa blockade resulted in superior inhibition of inflammation and cardiac marker release, which was accompanied by superior platelet inhibition immediately after percutaneous coronary intervention compared with a strategy of clopidogrel alone."5.12Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study. ( Bliden, KP; Gurbel, PA; Tantry, US, 2006)
"In elective stenting without clopidogrel pretreatment, use of a GPIIb/IIIa inhibitor produces superior platelet inhibition and lower myocardial necrosis compared with high-dose (600 mg) or standard-dose (300 mg) clopidogrel loading alone."5.11Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. ( Bliden, KP; Gurbel, PA; Hayes, KM; Tantry, US; Yoho, JA; Zaman, KA, 2005)
"In patients with NSTE-ACS undergoing early invasive strategy, the adjunctive administration of upstream tirofiban did not reduce the peak values and the cumulative release of myocardial necrosis markers, compared with aspirin, heparin, and clopidogrel given on admission and associated with selective use of abciximab just before PCI."5.11Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstrea ( Badia, T; Bellandi, F; Dabizzi, RP; De Servi, S; Leoncini, M; Maioli, M; Politi, A; Toso, A, 2005)
" This review examines the role of clopidogrel in decreasing periprocedural myonecrosis following percutaneous coronary intervention (PCI)."4.85Use of clopidogrel in the reduction of myocardial damage during percutaneous coronary intervention. ( Dasgupta, A; Mukherjee, D, 2009)
"We sought to evaluate the influence of platelet reactivity after clopidogrel, as assessed by the VerifyNow point-of-care assay (Accumetrics, San Diego, California), on myonecrosis in low-to-intermediate risk patients undergoing percutaneous coronary intervention (PCI)."3.76Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention. ( Barbato, E; D'Ambrosio, A; Di Sciascio, G; Gatto, L; Mangiacapra, F; Patti, G; Ricottini, E; Vizzi, V; Wijns, W, 2010)
" Thus, we assessed whether platelet function under high shear rates (collagen adenosine diphosphate closure times [CADP-CTs]) measured with the platelet function analyzer (PFA-100) may be enhanced in patients with myocardial infarction (MI) and whether it may predict the extent of myocardial damage as measured by creatine kinase (CK-MB) or troponin T (TnT) levels."3.72Platelet function predicts myocardial damage in patients with acute myocardial infarction. ( Domanovits, H; Frossard, M; Fuchs, I; Hsieh, K; Jilma, B; Laggner, AN; Leitner, JM; Losert, H; Schreiber, W; Vlcek, M, 2004)
" A significant dose-response was also observed for the vasodilator-stimulated phosphoprotein index, a measure of P2Y(12) receptor inhibition."2.72A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) t ( Bal-dit-Sollier, C; Beygui, F; Collet, JP; Drouet, L; Henry, P; Lellouche, N; Meuleman, C; Milleron, O; Montalescot, G; Sideris, G; Slama, M; Steg, PG, 2006)
"Aspirin response was assessed by measuring the residual ability of platelets to generate thromboxane, calculated as the difference between thromboxane B2 levels in serum and plasma, [TxB2]S-P."1.42Dual antiplatelet response during PCI: VerifyNow P2Y12 predicts myocardial necrosis and thromboxane B2 generation confirms wide variation in aspirin response. ( Good, RI; Goodall, AH; James, TE; McConnachie, A; McGarrity, A; Miller, H; Oldroyd, KG, 2015)

Research

Studies (22)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's16 (72.73)29.6817
2010's6 (27.27)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Leoncini, M2
Toso, A2
Maioli, M2
Tropeano, F1
Badia, T2
Villani, S1
Bellandi, F2
Good, RI1
McGarrity, A1
James, TE1
Miller, H1
McConnachie, A1
Goodall, AH1
Oldroyd, KG1
Ivandic, BT1
Kurz, K1
Keck, F1
Staritz, P1
Lehrke, S1
Katus, HA1
Giannitsis, E1
Yong, G1
Rankin, J1
Ferguson, L1
Thom, J1
French, J1
Brieger, D1
Chew, DP1
Dick, R1
Eccleston, D1
Hockings, B1
Walters, D1
Whelan, A1
Eikelboom, JW1
Dasgupta, A1
Mukherjee, D1
Saw, J1
Densem, C1
Walsh, S1
Jokhi, P1
Starovoytov, A1
Fox, R1
Wong, G1
Buller, C1
Ricci, D1
Mancini, GB1
Fung, A1
Stellos, K1
Bigalke, B1
Stakos, D1
Henkelmann, N1
Gawaz, M1
Sullivan, BP1
Wang, R1
Tawfik, O1
Luyendyk, JP1
Mangiacapra, F1
Barbato, E1
Patti, G2
Gatto, L1
Vizzi, V1
Ricottini, E1
D'Ambrosio, A1
Wijns, W1
Di Sciascio, G2
Bordeaux, JS1
Martires, KJ1
Goldberg, D1
Pattee, SF1
Fu, P1
Maloney, ME1
Frossard, M1
Fuchs, I1
Leitner, JM1
Hsieh, K1
Vlcek, M1
Losert, H1
Domanovits, H1
Schreiber, W1
Laggner, AN1
Jilma, B1
Gurbel, PA2
Bliden, KP2
Zaman, KA1
Yoho, JA1
Hayes, KM1
Tantry, US2
Politi, A1
De Servi, S1
Dabizzi, RP1
Gulec, S1
Ozdol, C1
Rahimov, U1
Atmaca, Y1
Kumbasar, D1
Erol, C1
Pasceri, V1
Nusca, A1
Defuentes, G1
Lecoules, S1
Vedrine, L1
Coutant, G1
Baranger, B1
Algayres, JP1
Moore, RK1
Lowe, R1
Grayson, AD1
Morris, JL1
Perry, RA1
Stables, RH1
Montalescot, G1
Sideris, G1
Meuleman, C1
Bal-dit-Sollier, C1
Lellouche, N1
Steg, PG1
Slama, M1
Milleron, O1
Collet, JP1
Henry, P1
Beygui, F1
Drouet, L1
Ersoy, A1
Sevin, K1
Sevin, A1
Serel, S1
Buch, AN1
Singh, S1
Roy, P1
Javaid, A1
Smith, KA1
George, CE1
Pichard, AD1
Satler, LF1
Kent, KM1
Suddath, WO1
Waksman, R1
Gulmez, O1
Yildirir, A1
Kaynar, G1
Konas, D1
Aydinalp, A1
Ertan, C1
Ozin, B1
Muderrisoglu, H1

Clinical Trials (8)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Protective Effect of Rosuvastatin and Antiplatelet Therapy On Contrast-induced Nephropathy and Myocardial Damage in Patients With Acute Coronary Syndrome Undergoing Coronary Intervention; PRATO-ACS Trial[NCT01185938]Phase 4500 participants (Actual)Interventional2010-07-31Completed
Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention[NCT00111566]Phase 4624 participants (Actual)Interventional2004-12-31Completed
Effects of Ticagrelor Versus Prasugrel on Coronary Microcirculation in Patients Undergoing Elective Percutaneous Coronary Intervention: Results of the PROtecting MICROcirculation During Coronary Angioplasty (PROMICRO)-3 Randomised Study[NCT05643586]Phase 450 participants (Actual)Interventional2017-12-01Completed
The Effect of Ticagrelor on Acute Coronary Syndrome Patients With Clopidogrel Resistance Undergoing Percutaneous Coronary Intervention[NCT01812330]Phase 3180 participants (Anticipated)Interventional2013-01-31Recruiting
A Pilot Study of The Effects of a Single High Dose Bolus Tirofiban in Diabetic Patients Undergoing Elective Percutaneous Coronary Intervention[NCT00407771]Phase 444 participants (Anticipated)Interventional2007-11-30Not yet recruiting
"Evaluation of Antiplatelet Effects and Safety of Intraoperative Administration of Ticagrelor Versus Clopidogrel in Patients Undergoing One-stop Hybrid Coronary Revascularization"[NCT02513004]Phase 460 participants (Anticipated)Interventional2015-06-30Recruiting
Non-randomized, Open-label, Historical Control, Single Group Assignment Trial of a Reduced Dose of Unfractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions[NCT00735280]Phase 42,505 participants (Actual)Interventional2008-08-31Completed
Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis.[NCT00360386]Phase 2110 participants Interventional2004-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

2 reviews available for ticlopidine and Necrosis

ArticleYear
Use of clopidogrel in the reduction of myocardial damage during percutaneous coronary intervention.
    Vascular health and risk management, 2009, Volume: 5, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Biomarkers; Clopidogrel; Creatine Kinase, MB Form; Drug Administrati

2009
[Prevention of periprocedural myocardial damage in patients undergoing percutaneous coronary intervention].
    Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology, 2005, Volume: 6, Issue:9

    Topics: Actuarial Analysis; Adenosine; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Anticholestere

2005

Trials

9 trials available for ticlopidine and Necrosis

ArticleYear
Early high-dose rosuvastatin and cardioprotection in the protective effect of rosuvastatin and antiplatelet therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome (PRATO-ACS) study.
    American heart journal, 2014, Volume: 168, Issue:5

    Topics: Acute Coronary Syndrome; Acute Kidney Injury; Cardiotonic Agents; Clopidogrel; Contrast Media; Coron

2014
Tirofiban optimizes platelet inhibition for immediate percutaneous coronary intervention in high-risk acute coronary syndromes.
    Thrombosis and haemostasis, 2008, Volume: 100, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease

2008
Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin
    American heart journal, 2009, Volume: 157, Issue:1

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Fema

2009
The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy.
    JACC. Cardiovascular interventions, 2008, Volume: 1, Issue:6

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease

2008
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
    Circulation, 2005, Mar-08, Volume: 111, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen

2005
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
    Circulation, 2005, Mar-08, Volume: 111, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen

2005
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
    Circulation, 2005, Mar-08, Volume: 111, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen

2005
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
    Circulation, 2005, Mar-08, Volume: 111, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen

2005
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
    Circulation, 2005, Mar-08, Volume: 111, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen

2005
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
    Circulation, 2005, Mar-08, Volume: 111, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen

2005
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
    Circulation, 2005, Mar-08, Volume: 111, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen

2005
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
    Circulation, 2005, Mar-08, Volume: 111, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen

2005
Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study.
    Circulation, 2005, Mar-08, Volume: 111, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coronary; Cardiovascular Agen

2005
Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstrea
    American heart journal, 2005, Volume: 150, Issue:3

    Topics: Abciximab; Acute Disease; Aged; Angina, Unstable; Antibodies, Monoclonal; Clopidogrel; Creatine Kina

2005
A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) t
    Journal of the American College of Cardiology, 2006, Sep-05, Volume: 48, Issue:5

    Topics: Acute Disease; Adenosine Diphosphate; Aged; Biomarkers; Clopidogrel; Dose-Response Relationship, Dru

2006
A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) t
    Journal of the American College of Cardiology, 2006, Sep-05, Volume: 48, Issue:5

    Topics: Acute Disease; Adenosine Diphosphate; Aged; Biomarkers; Clopidogrel; Dose-Response Relationship, Dru

2006
A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) t
    Journal of the American College of Cardiology, 2006, Sep-05, Volume: 48, Issue:5

    Topics: Acute Disease; Adenosine Diphosphate; Aged; Biomarkers; Clopidogrel; Dose-Response Relationship, Dru

2006
A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) t
    Journal of the American College of Cardiology, 2006, Sep-05, Volume: 48, Issue:5

    Topics: Acute Disease; Adenosine Diphosphate; Aged; Biomarkers; Clopidogrel; Dose-Response Relationship, Dru

2006
Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study.
    Journal of the American College of Cardiology, 2006, Dec-05, Volume: 48, Issue:11

    Topics: Aged; Biomarkers; Blood Platelets; C-Reactive Protein; Clopidogrel; Creatine Kinase, MB Form; Eptifi

2006
Effects of persistent platelet reactivity despite aspirin therapy on cardiac troponin I and creatine kinase-MB levels after elective percutaneous coronary interventions.
    Journal of thrombosis and thrombolysis, 2008, Volume: 25, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Cre

2008

Other Studies

11 other studies available for ticlopidine and Necrosis

ArticleYear
Dual antiplatelet response during PCI: VerifyNow P2Y12 predicts myocardial necrosis and thromboxane B2 generation confirms wide variation in aspirin response.
    Thrombosis research, 2015, Volume: 135, Issue:6

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies

2015
Platelet-bound P-selectin expression in patients with coronary artery disease: impact on clinical presentation and myocardial necrosis, and effect of diabetes mellitus and anti-platelet medication.
    Journal of thrombosis and haemostasis : JTH, 2010, Volume: 8, Issue:1

    Topics: Acute Coronary Syndrome; Angina Pectoris; Aspirin; Biomarkers; Blood Platelets; Clopidogrel; Coronar

2010
Protective and damaging effects of platelets in acute cholestatic liver injury revealed by depletion and inhibition strategies.
    Toxicological sciences : an official journal of the Society of Toxicology, 2010, Volume: 115, Issue:1

    Topics: 1-Naphthylisothiocyanate; Animals; Antibodies, Monoclonal; Biomarkers; Blood Coagulation; Blood Plat

2010
Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention.
    JACC. Cardiovascular interventions, 2010, Volume: 3, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Biomarkers; Blood Platelets; Clopidogrel; Coronary Artery Dise

2010
Prospective evaluation of dermatologic surgery complications including patients on multiple antiplatelet and anticoagulant medications.
    Journal of the American Academy of Dermatology, 2011, Volume: 65, Issue:3

    Topics: Aged; Ambulatory Surgical Procedures; Antibiotic Prophylaxis; Anticoagulants; Clopidogrel; Dermatolo

2011
Platelet function predicts myocardial damage in patients with acute myocardial infarction.
    Circulation, 2004, Sep-14, Volume: 110, Issue:11

    Topics: Abciximab; Adenosine Diphosphate; Aged; Antibodies, Monoclonal; Anticoagulants; Aspirin; Cardiovascu

2004
Myonecrosis after elective percutaneous coronary intervention: effect of clopidogrel-statin interaction.
    The Journal of invasive cardiology, 2005, Volume: 17, Issue:11

    Topics: Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Creatine Kinase, MB Form; Cytochrome P-450 CYP3A;

2005
[Accelerated atheroma with prednisone and clopidogrel].
    Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:3 Pt 1

    Topics: Aged; Atherosclerosis; Carotid Stenosis; Clopidogrel; Endarterectomy; Giant Cell Arteritis; Glucocor

2006
A study comparing the incidence and predictors of creatine kinase MB and troponin T release after coronary angioplasty. Does Clopidogrel preloading reduce myocardial necrosis following elective percutaneous coronary intervention?
    International journal of cardiology, 2007, Mar-02, Volume: 116, Issue:1

    Topics: Angioplasty, Balloon, Coronary; Biomarkers; Clopidogrel; Cohort Studies; Coronary Disease; Creatine

2007
Effects of clopidogrel on survival of rat skin flaps.
    Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 2007, Volume: 60, Issue:8

    Topics: Animals; Clopidogrel; Graft Survival; Male; Necrosis; Platelet Aggregation Inhibitors; Random Alloca

2007
Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention.
    The American journal of cardiology, 2007, Jun-01, Volume: 99, Issue:11

    Topics: Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Coronary; Aspirin; Biomarkers;

2007